Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$40.46 USD
-0.71 (-1.72%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $40.46 0.00 (0.00%) 5:42 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$40.46 USD
-0.71 (-1.72%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $40.46 0.00 (0.00%) 5:42 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Zacks News
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View
by Zacks Equity Research
Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.
Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 44.44% and 2.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes (TNDM) Gets FDA Nod for Tandem Mobi System
by Zacks Equity Research
Tandem Diabetes (TNDM) receives FDA clearance for the world's smallest AID system, Tandem Mobi.
Strength Seen in Tandem Diabetes Care, Inc. (TNDM): Can Its 8.9% Jump Turn into More Strength?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.
Tandem Diabetes (TNDM) Q1 Earnings Miss, Gross Margin Dips
by Zacks Equity Research
According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -12.50% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes (TNDM) Gains on Pump Sales, Margin Woe Stays
by Zacks Equity Research
Tandem Diabetes (TNDM) is now increasing its renewal numbers both in volume and rates.
Why Is Masimo (MASI) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2
by Zacks Equity Research
Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.
Tandem Diabetes (TNDM) Q4 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 50% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Tops Q3 Earnings Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 11.90% and 5.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Tandem (TNDM) to Expand Global Insulin Pump Base With New Buy
by Zacks Equity Research
The AMF Medical acquisition will help Tandem (TNDM) advance with its sustainability objectives by offering an additional pump that minimizes electronic and battery waste generation.
Tandem Diabetes (TNDM) Q3 Earnings Miss, Sales View Cut
by Zacks Equity Research
Tandem Diabetes (TNDM) defers $0.6 million of United States pump sales as a result of Tandem Choice.
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -800% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include Tandem Diabetes Care, Krispy Kreme, Caesars Entertainment and Vestas Wind Systems
by Zacks Equity Research
Tandem Diabetes Care, Krispy Kreme, Caesars Entertainment and Vestas Wind Systems are part of Zacks Screen of the week article.
RxSight, Inc. (RXST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
RxSight, Inc. (RXST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Get Rid of Your Stress by Dumping These 4 Toxic Stocks
by Rimmi Singhi
Detoxify your portfolio by selling stocks like Tandem Diabetes (TNDM) Krispy Kreme (DNUT), Caesars Entertainment (CZR) and Vestas Wind (VWDRY).